KBBT.F Stock Overview
Kubota Pharmaceutical Holdings Co., Ltd. develops portfolio of drugs and devices worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Kubota Pharmaceutical Holdings Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥0.96 |
| 52 Week High | JP¥1.95 |
| 52 Week Low | JP¥0.95 |
| Beta | 1.19 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | -80.80% |
| Change since IPO | -85.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| KBBT.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -3.3% | -3.1% |
| 1Y | n/a | 11.3% | 20.9% |
Return vs Industry: Insufficient data to determine how KBBT.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how KBBT.F performed against the US Market.
Price Volatility
| KBBT.F volatility | |
|---|---|
| KBBT.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: KBBT.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine KBBT.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 8 | Ryo Kubota | www.kubotaholdings.co.jp |
Kubota Pharmaceutical Holdings Co., Ltd. develops portfolio of drugs and devices in the ophthalmic field worldwide. Its product pipeline comprises emixustat hydrochloride, which is in Phase III clinical stage used for the treatment of stargardt disease, and Phase II clinical stage used for the treatment of proliferative diabetic retinopathy. The company is also developing remote retinal monitoring device, a home-based and patient self-monitoring optical coherence tomography devices to treat wet age-related macular degeneration and diabetic macular edema, which brings retinal edema and reduction in visual acuity; and wearable device for myopia control.
Kubota Pharmaceutical Holdings Co., Ltd. Fundamentals Summary
| KBBT.F fundamental statistics | |
|---|---|
| Market cap | US$46.04m |
| Earnings (TTM) | -US$15.22m |
| Revenue (TTM) | US$62.32k |
738.8x
P/S Ratio-3.0x
P/E RatioIs KBBT.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KBBT.F income statement (TTM) | |
|---|---|
| Revenue | JP¥8.25m |
| Cost of Revenue | JP¥1.52b |
| Gross Profit | -JP¥1.51b |
| Other Expenses | JP¥505.47m |
| Earnings | -JP¥2.02b |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -36.69 |
| Gross Margin | -18,299.41% |
| Net Profit Margin | -24,423.38% |
| Debt/Equity Ratio | 0% |
How did KBBT.F perform over the long term?
See historical performance and comparison